A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

Prior treatment

• Participant is mentally or legally incapacitated.
  • Prior/Concomitant Therapy
• Any warnings and contraindications that apply based on Loestrin prescribing information.
  • Prior/Concurrent Clinical Study Experience
• Exposure to more than 4 new investigational products (including long-acting investigational products) within 12 months prior to the first dosing day.
• Current enrollment or past participation in another investigational study in which an investigational intervention was administered within the last 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) before signing of consent (or screening) any other clinical study.
• Participant has donated or lost blood (\>500 millilitres (mL)) or blood products within 2 months (56-day period) prior to Day -1 admission or has donated plasma within 30 days prior to first OC administration.
• Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of \>7 units for females. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
• Regular use of known drugs of abuse.

Other illness

• History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs.
• Lymphoma, leukemia, or any malignancy within the past 5 years with some exceptions
• Breast cancer or in remission within the past 10 years.
• Current or chronic history of liver disease or known hepatic or biliary abnormalities with some exceptions.
• Any personal and/or family history of thrombophilia or blood clots
• History of seizure(s).
• Any known or suspected pre-existing psychiatric condition, including depression, anxiety, and/or insomnia/sleep disturbances.
• Subjects with history of drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions will be excluded.
• Positive Human immunodeficiency virus 1 (HIV-1) antibody test.

Lab values

• Medical history of cardiac arrhythmias or cardiac disease or a family and personal history of long QT syndrome.

Other

• Current enrollment or past participation in this clinical study. Unwillingness or inability to follow the procedures outlined in the protocol.
• Pregnant at screening) or lactating.
• POCBP who are unwilling or unable to use an appropriate non-hormonal method of highly effective contraception from at least Day 1 of Treatment Period 1 until 14 days after the last dose of VH4524184.

• Healthy participants 18 to 45 years of age
• POCBP with intact ovarian function by medical history and history of regular menstrual cycles for the past 12
• Body weight greater than or equal to (≥) 45 kilograms (kg) and Body mass index (BMI) within the range of 18.5 to 32.0 kg/m2
• Female participants of childbearing potential must use approved highly effective non-hormonal forms of birth control.
• Capable of giving signed informed consent.